Opposite expression of NCOA4 in glioblastoma tissues and cell lines

Guangtang Chen ¹, Xueping Shi ¹, Xi Zeng ¹

⁰Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China.

International Immunopharmacology +

|

October 9, 2024

View abstract on PubMed

Summary

Nuclear receptor coactivator 4 (NCOA4) expression differs between glioblastoma (GBM) tissues and cells, suggesting ferroptosis may occur in non-tumor cells, impacting GBM treatment strategies.

Area Of Science

Oncology
Cell Death Mechanisms
Molecular Biology

Background

Ferroptosis, a prevalent programmed cell death, is linked to glioblastoma (GBM) malignancy and immune suppression.
Nuclear receptor coactivator 4 (NCOA4) is a key regulator of ferroptosis, but its role in GBM tissues is not well understood.

Purpose Of The Study

To investigate the expression pattern of NCOA4 in glioblastoma (GBM) tissues and cell lines.
To explore the implications of NCOA4 expression on ferroptosis and therapeutic resistance in GBM.

Main Methods

Comparative analysis of NCOA4 expression in GBM tissues versus GBM cell lines (U87-MG, U251, LN229).
Bioinformatics analysis and experimental validation.
Assessment of ferroptosis in tumor and non-tumor cells within GBM tissues.

Main Results

NCOA4 expression was elevated in GBM tissues but decreased in GBM cell lines.
This inverse expression pattern suggests ferroptosis may be more pronounced in non-tumor cells within the GBM microenvironment.
Findings challenge the direct correlation between NCOA4 levels and tumor cell ferroptosis in GBM.

Conclusions

The observed NCOA4 expression pattern in GBM tissues may indicate increased ferroptosis in non-tumor cells, not tumor cells.
This finding has significant implications for therapeutic strategies targeting ferroptosis in GBM.
Further research is warranted to understand the role of NCOA4 in GBM and other tumor types.

Keywords:

Biomarker Cancer therapy Ferroptosis Glioblastoma NCOA4